It was never a secret that Boston Scientific (Natick, Massachusetts) wanted to dip its fingers into the strategically critical renal denervation pool – the company already has a renal denervation system in development with a CE mark planned for next year – but analysts and other industry watchdogs were a bit surprised Thursday morning when the company reported an agreement to acquire Vessix Vascular (Laguna Hills, California) for up to $425 million. The acquisition is expected to close by the end of the month. Read More
